CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 933 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01955161
NCT01955161Phase 3Completed
CompareCT.gov

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

H. Lundbeck A/S·interventional·Posted Oct 7, 2013·Updated Sep 19, 2017

In Brief

A Phase 3 clinical trial evaluating Placebo and Idalopirdine for Alzheimer's Disease. Completed, enrolled 933 participants across 137 sites in 16 countries.

Detailed Summary

To establish efficacy of idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesArgentina, Belgium, Bulgaria, Canada, Chile, Czechia, Denmark, France, Germany, Italy, Poland, Romania, South Africa, Spain, Ukraine, United States
CollaboratorsOtsuka Pharmaceutical Co., Ltd.

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 7, 2013
Enrollment StartOct 1, 2013
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.7 years ago

Interventions

Placebodrug

Once daily, matching placebo capsules, orally

Idalopirdinedrug

Once daily, encapsulated tablets, orally